Skip to main content
. 2017 Jul 31;2017(7):CD012744. doi: 10.1002/14651858.CD012744

3.7. Analysis.

Comparison 3 Amifostine versus no treatment/placebo, Outcome 7 Overall survival ‐ narrative data.

Overall survival ‐ narrative data
Study Time point Amifostine Control Comments
Haddad 2009 Median follow‐up 34 months after radiotherapy, minimum 26 months     "No differences noted"
Jellema 2006 24 months 3 times weekly = 84%
5 times weekly = 58%
70% Reported narratively rather than as a risk ratio due to differing results in the amifostine arms